Markets:

Overview

News

Currencies

International

Treasuries

Erasca, Inc. - Common Stock (NQ:ERAS)

9.830 +0.210 (+2.18%)

Streaming Delayed Price Updated: 1:14 PM EST, Jan 20, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Erasca, Inc. - Common Stock

< Previous 1 2 3 4 Next >

Erasca Insider Sells $671K as Stock Jumps 189% This Past Year ↗

January 13, 2026

This oncology biotech developing targeted cancer therapies saw a key insider significantly trim their direct equity stake.

Via The Motley Fool

Topics Regulatory Compliance

Get insights into the top gainers and losers of Thursday's after-hours session. ↗

January 08, 2026

Via Chartmill

The $20 Billion Question: Revolution Medicines Surges as Big Pharma Circles the Pan-RAS Leader

January 08, 2026

The first week of 2026 has set the biotech sector ablaze, with Revolution Medicines (NASDAQ: RVMD) finding itself at the epicenter of a high-stakes acquisition tug-of-war. Shares of the Redwood...

Via MarketMinute

Topics Intellectual Property

ERAS Stock Earnings: Erasca Misses EPS for Q2 2024 ↗

August 12, 2024

ERAS stock results show that Erasca missed analyst estimates for earnings per share the second quarter of 2024.

Via InvestorPlace

ERAS Stock Earnings: Erasca Misses EPS for Q1 2024 ↗

May 08, 2024

ERAS stock results show that Erasca missed analyst estimates for earnings per share the first quarter of 2024.

Via InvestorPlace

ERAS Stock Earnings: Erasca Beats EPS for Q4 2023 ↗

March 27, 2024

ERAS stock results show that Erasca beat analyst estimates for earnings per share the fourth quarter of 2023.

Via InvestorPlace

Get insights into the top gainers and losers of Thursday's pre-market session. ↗

January 08, 2026

Via Chartmill

Stay updated with the stocks that are on the move in today's after-hours session. ↗

January 07, 2026

Via Chartmill

Targeted Cancer Therapies Gain Momentum as Precision Market Surges Past $106B

November 19, 2025

EQNX::TICKER_START (NASDAQ:ONCY),(NASDAQ:ALXO),(NASDAQ:ERAS),(NASDAQ:IMRX),(NASDAQ:PRLD) EQNX::TICKER_END

Via FinancialNewsMedia

Targeted Cancer Therapies Gain Momentum as Precision Market Surges Past $106B

November 19, 2025

From FN Media Group LLC

Via GlobeNewswire

Fidus Investment, Rocket Companies And Other Big Stocks Moving Lower In Thursday's Pre-Market Session ↗

October 02, 2025

Via Benzinga

Why Concorde International Group Shares Are Trading Higher By 55%; Here Are 20 Stocks Moving Premarket ↗

October 02, 2025

Via Benzinga

This Accenture Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday ↗

September 03, 2025

Via Benzinga

Erasca Narrows Loss 46% in Fiscal Q2 ↗

August 12, 2025

Via The Motley Fool

Wolverine World Wide, Pacira BioSciences And Other Big Stocks Moving Higher On Monday ↗

April 21, 2025

Via Benzinga

This Spotify Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday ↗

March 26, 2025

Via Benzinga

Stellantis, PG&E And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗

December 02, 2024

Via Benzinga

e.l.f. Beauty Posts Upbeat Earnings, Joins Nvidia, LiveRamp Holdings, Borr Drilling And Other Big Stocks Moving Higher On Thursday ↗

May 23, 2024

Via Benzinga

$1.5M Bet On This Healthcare Stock? Check Out These 4 Penny Stocks Insiders Are Aggressively Buying ↗

May 23, 2024

Via Benzinga

DXC Technology Issues Weak Outlook, Joins Take-Two Interactive And Other Big Stocks Moving Lower In Friday's Pre-Market Session ↗

May 17, 2024

Via Benzinga

Erasca Reports First Quarter 2024 Business Updates and Financial Results

May 08, 2024

From Erasca, Inc.

Via GlobeNewswire

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

April 19, 2024

Via Benzinga

Erasca Announces $45 Million Oversubscribed Private Placement Financing

March 27, 2024

Funding from new and existing investors extends anticipated cash runway into H2 2026

From Erasca, Inc.

Via GlobeNewswire

Erasca Reports Fourth Quarter 2023 and Full Year 2023 Business Updates and Financial Results

March 27, 2024

From Erasca, Inc.

Via GlobeNewswire

Erasca Announces Two Clinical Trial Collaboration and Supply Agreements for Trametinib to Evaluate Naporafenib Combination in SEACRAFT-1 and SEACRAFT-2 Trials

February 14, 2024

From Erasca, Inc.

Via GlobeNewswire

Erasca to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

February 01, 2024

From Erasca, Inc.

Via GlobeNewswire

Erasca to Present at the 42nd Annual J.P. Morgan Healthcare Conference

January 03, 2024

From Erasca, Inc.

Via GlobeNewswire

3 Penny Stocks You’ll Regret Not Buying Soon: December Edition ↗

December 20, 2023

Consider the pros and cons of buying these penny stocks, which can deliver risk-adjusted returns to investors' portfolios.

Via InvestorPlace

RiskOn International And 3 Other Stocks Under $2 Insiders Are Buying ↗

December 11, 2023

The Dow Jones closed higher by over 100 points on Friday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders...

Via Benzinga

Topics Stocks

Erasca Granted FDA Fast Track Designation for Pan-RAF Inhibitor Naporafenib in Patients with Advanced NRAS-Mutated Melanoma

December 11, 2023

From Erasca, Inc.

Via GlobeNewswire

< Previous 1 2 3 4 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.